Attana will participate at Stora Aktiedagen digitalt on December 2[nd] to discuss the upcoming rights issue and future plans
Attana will participate at Aktiespararna’s Stora Aktiedagen digitalt to deliver a company presentation and answer questions. It will be a 20-minute presentation followed by a 10-minute Q&A from 09.00 to 09.30 on December 2nd.
The presentation will primarily focus on the upcoming rights issue and the future plans it enables. More information about the presentation and a link to the livestream of the event will be published in an upcoming press release.
For more information, please contact:
Teodor Aastrup, CEO Attana AB
tel: + 46 8 674 57 00
The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.
Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact firstname.lastname@example.org